Zacks Research Analysts Reduce Earnings Estimates for HealthEquity, Inc. (NASDAQ:HQY)

HealthEquity, Inc. (NASDAQ:HQY) – Zacks Research decreased their Q1 2026 earnings per share (EPS) estimates for HealthEquity in a report released on Monday, September 30th. Zacks Research analyst R. Department now forecasts that the company will earn $0.68 per share for the quarter, down from their previous forecast of $0.69. The consensus estimate for HealthEquity’s current full-year earnings is $2.25 per share.

Several other research firms have also recently issued reports on HQY. Wells Fargo & Company increased their price objective on HealthEquity from $107.00 to $110.00 and gave the stock an “overweight” rating in a research report on Thursday, June 20th. Bank of America cut their price objective on HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Raymond James upped their target price on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Friday, June 7th. Barrington Research reissued an “outperform” rating and issued a $105.00 target price on shares of HealthEquity in a report on Friday, September 20th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $103.83.

HealthEquity Trading Down 1.2 %

NASDAQ:HQY opened at $78.18 on Wednesday. The stock has a fifty day moving average price of $76.46 and a two-hundred day moving average price of $79.20. The stock has a market capitalization of $6.80 billion, a price-to-earnings ratio of 85.40, a PEG ratio of 1.25 and a beta of 0.52. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10. HealthEquity has a 1 year low of $61.81 and a 1 year high of $88.26.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.16. The firm had revenue of $299.93 million during the quarter, compared to analysts’ expectations of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%.

Institutional Trading of HealthEquity

A number of hedge funds have recently added to or reduced their stakes in the business. Motley Fool Asset Management LLC raised its holdings in shares of HealthEquity by 3,001.0% in the 1st quarter. Motley Fool Asset Management LLC now owns 3,762,064 shares of the company’s stock worth $307,097,000 after purchasing an additional 3,640,748 shares during the period. Vaughan Nelson Investment Management L.P. purchased a new position in shares of HealthEquity in the 1st quarter worth about $49,443,000. Wasatch Advisors LP raised its holdings in shares of HealthEquity by 8.3% in the 1st quarter. Wasatch Advisors LP now owns 7,409,080 shares of the company’s stock worth $604,803,000 after purchasing an additional 569,249 shares during the period. Mackenzie Financial Corp raised its holdings in shares of HealthEquity by 16.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,364,521 shares of the company’s stock worth $203,822,000 after purchasing an additional 325,906 shares during the period. Finally, Generate Investment Management Ltd purchased a new position in shares of HealthEquity in the 2nd quarter worth about $24,184,000. 99.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at HealthEquity

In related news, Vice Chairman Stephen Neeleman sold 35,000 shares of the stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the sale, the insider now owns 89,769 shares of the company’s stock, valued at $7,168,952.34. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other HealthEquity news, Director Frank Corvino sold 1,247 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total value of $100,084.22. Following the sale, the director now directly owns 4,823 shares of the company’s stock, valued at approximately $387,093.98. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the firm’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $79.86, for a total value of $2,795,100.00. Following the completion of the sale, the insider now directly owns 89,769 shares in the company, valued at $7,168,952.34. The disclosure for this sale can be found here. Insiders have sold a total of 43,952 shares of company stock valued at $3,526,147 over the last quarter. Insiders own 2.20% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.